Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study.

@article{Weinblatt2006SafetyOT,
  title={Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study.},
  author={M. Weinblatt and B. Combe and A. Covucci and R. Aranda and J. Becker and E. Keystone},
  journal={Arthritis and rheumatism},
  year={2006},
  volume={54 9},
  pages={
          2807-16
        }
}
  • M. Weinblatt, B. Combe, +3 authors E. Keystone
  • Published 2006
  • Medicine
  • Arthritis and rheumatism
  • OBJECTIVE To assess the safety of abatacept, a selective costimulation modulator, in patients with active rheumatoid arthritis (RA) who had been receiving > or =1 traditional nonbiologic and/or biologic disease-modifying antirheumatic drugs (DMARDs) approved for the treatment of RA for at least 3 months prior to entry into the study. METHODS This was a 1-year, multicenter, randomized, double-blind, placebo-controlled trial. Patients were randomized 2:1 to receive abatacept at a fixed dose… CONTINUE READING
    369 Citations

    Paper Mentions

    INTERVENTIONAL CLINICAL TRIAL
    This is an open-label trial investigating the efficacy and safety of abatacept in ankylosing spondylitis. It is planned to treat 30 patients with ankylosing spondylitis from baseline up… Expand
    ConditionsAnkylosing Spondylitis
    InterventionDrug
    Neue Option in der Behandlung der rheumatoiden Arthritis: Abatacept, ein selektiver Modulator der T-Zell-Kostimulation
    • 2
    • Highly Influenced
    Abatacept: A Review of its Use in the Management of Rheumatoid Arthritis
    • 41
    • Highly Influenced
    Abatacept: a biologic immune modulator for rheumatoid arthritis
    • 6
    ABATACEPT IN FOCUS
    • 1
    • PDF
    Effectiveness and safety of abatacept in moderate to severe rheumatoid arthritis.
    • 2
    Update on Abatacept: A Selective Costimulation Modulator for Rheumatoid Arthritis
    • 28

    References

    SHOWING 1-10 OF 16 REFERENCES
    Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition.
    • 1,121
    • PDF
    Effects of Abatacept in Patients with Methotrexate-Resistant Active Rheumatoid Arthritis
    • 702
    • PDF
    Cytokine pathways and joint inflammation in rheumatoid arthritis.
    • 2,004
    American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis.
    • 2,441
    • PDF
    The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis.
    • 19,005
    The role of novel T cell costimulatory pathways in autoimmunity and transplantation.
    • 171
    • PDF